RedHill Biopharma Ltd.: Strategic Expansion from R&D to Sales of Drugs in the US

• jaimeuss_admin
• 17 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85

• jaimeuss_admin
• 16 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Enlight Renewable Energy Ltd.: The Company may double its revenues within two years; price target is NIS 2.30.

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Energix Renewable Energies Ltd.: Combining green energy growth opportunities with Fix Assets returns

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading

DNA Biomedical Solutions Ltd.: The company and its holdings can become a major force in the osteoporosis care market, pending success in next year’s clinical trials.

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Vonetize Plc: An Investment Opportunity in the Fast-Growing VOD/IPTV Domain

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

Brainsway Ltd.: Market Trends Drive Revenue Growth. An Opportunity for Increased Value based on the scenario of the Successful Execution of the New Business Model

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

BiolineRx. An Opportunity to Invest in the Development of Unique Cancer Treatment Technologies

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading